Crazy to sell under $8.5-9 "De

2023-08-16

Crazy to sell under $8.5-9 "Delcath Systems price target raised to $18 from $14 at Canaccord
Canaccord raised the firm's price target on Delcath Systems to $18 from $14 and keeps a Buy rating on the shares. The firm noted they announced approval of Hepzato, a drug/device combination that delivers high doses of melphalan to the liver for the treatment of unresectable metastatic uveal melanoma (mUM, aka metastatic ocular melanoma, mOM) with metastases to the liver. The label appears clean, and includes both treatment-naive and previously treated patients." $DELCATH SYSTEMS INC(DCTH)$

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":209539230052472,"tweetId":"209539230052472","gmtCreate":1692174843373,"gmtModify":1692174849175,"author":{"id":9000000000000186,"idStr":"9000000000000186","authorId":9000000000000186,"authorIdStr":"9000000000000186","name":"CharlesBaker","avatar":"https://static.tigerbbs.com/a1c16d0b9681dfcb63f65d353f063f28","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":69,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/7d46f2619c58009d2d4ad980c640e355","width":"500","height":"500"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/7d46f2619c58009d2d4ad980c640e355","width":"500","height":"500"}],"html":"<html><head></head><body>Crazy to sell under $8.5-9 \"Delcath Systems price target raised to $18 from $14 at Canaccord Canaccord raised the firm's price target on Delcath Systems to $18 from $14 and keeps a Buy rating on the shares. The firm noted they announced approval of Hepzato, a drug/device combination that delivers high doses of melphalan to the liver for the treatment of unresectable metastatic uveal melanoma (mUM, aka metastatic ocular melanoma, mOM) with metastases to the liver. The label appears clean, and includes both treatment-naive and previously treated patients.\" <a data-mention-id=\"DCTH\" class=\"teditor-mention\" data-mention-name=\"DELCATH SYSTEMS INC\" href=\"https://ttm.financial/S/DCTH\">$DELCATH SYSTEMS INC(DCTH)$</a> <img src=\"https://community-static.tradeup.com/news/7d46f2619c58009d2d4ad980c640e355\" tg-width=\"500\" tg-height=\"500\"></body></html>","htmlText":"<html><head></head><body>Crazy to sell under $8.5-9 \"Delcath Systems price target raised to $18 from $14 at Canaccord Canaccord raised the firm's price target on Delcath Systems to $18 from $14 and keeps a Buy rating on the shares. The firm noted they announced approval of Hepzato, a drug/device combination that delivers high doses of melphalan to the liver for the treatment of unresectable metastatic uveal melanoma (mUM, aka metastatic ocular melanoma, mOM) with metastases to the liver. The label appears clean, and includes both treatment-naive and previously treated patients.\" <a data-mention-id=\"DCTH\" class=\"teditor-mention\" data-mention-name=\"DELCATH SYSTEMS INC\" href=\"https://ttm.financial/S/DCTH\">$DELCATH SYSTEMS INC(DCTH)$</a> <img src=\"https://community-static.tradeup.com/news/7d46f2619c58009d2d4ad980c640e355\" tg-width=\"500\" tg-height=\"500\"></body></html>","text":"Crazy to sell under $8.5-9 \"Delcath Systems price target raised to $18 from $14 at Canaccord Canaccord raised the firm's price target on Delcath Systems to $18 from $14 and keeps a Buy rating on the shares. The firm noted they announced approval of Hepzato, a drug/device combination that delivers high doses of melphalan to the liver for the treatment of unresectable metastatic uveal melanoma (mUM, aka metastatic ocular melanoma, mOM) with metastases to the liver. The label appears clean, and includes both treatment-naive and previously treated patients.\" $DELCATH SYSTEMS INC(DCTH)$","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/209539230052472","repostId":0,"isVote":1,"tweetType":1,"viewCount":173,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["DCTH"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":498,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/209539230052472"}